• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 3, 2018

View Archived Issues

Regulatory front

Medicare payment cuts went into effect Monday for many hospitals participating in the 340B Drug Pricing Program after a federal district judge dismissed a last-minute effort to stop them. Read More

In the clinic

Selecta Biosciences Inc., of Watertown, Mass., said the FDA accepted the IND for a combination therapeutic candidate consisting of SVP-Rapamycin and LMB-100 (Selecta's SEL-403 product candidate) for the treatment of mesothelioma patients. Read More

Appointments and advancements

Spectrum Pharmaceuticals Inc., of Henderson, Nev., named Joseph W. Turgeon, president and CEO; Thomas J. Riga chief operating officer; and Stuart M. Krassner board chairman. Read More

Other news to note

Seattle Genetics Inc., of Bothell, Wash., said the FDA accepted for filing a supplemental BLA for Adcetris (brentuximab vedotin) in combination with chemotherapy for the front-line treatment of patients with advanced classical Hodgkin's lymphoma (HL). Read More

Financings

Dnanexus Inc., of Mountain View, Calif., said it closed a $58 million financing led by new investor Foresite Capital with strategic investment from Microsoft with existing investors GV (formerly Google Ventures), TPG Biotech, Wuxi Nextcode, Claremont Creek Ventures and Midcap Financial also participating. The company's global platform enables a network of enterprises to gain insight from large genomic and biomedical datasets. Read More

Aussie regenerative medicine company Regeneus employs a Japan-first strategy

PERTH, Australia – Unlike its Australian peers, regenerative medicine company Regeneus Ltd. is not focusing on the U.S. market. Instead, it's placing its bets on Japan first and then will move out to other territories. Read More

New CFDA regulations on vaccines to go into effect in the new year

HONG KONG – As it works to upgrade its biologics industry and the vaccine sector in particular, China updated the approval process for new products. Read More

Heads up for migraine data, Aimovig clearance this year; CGRPs transforming space

If Amgen Inc. and Novartis AG win approval of the calcitonin gene-related peptide (CGRP) inhibitor Aimovig (erenumab) – the PDUFA date is May 17 – the compound's price tag could provide guidance for others with CGRP monoclonal antibodies in their migraine pipelines, such as Alder Biopharmaceutical Inc., with eptinezumab due to yield phase III data this quarter from the PROMISE 2 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy 2) trial in chronic migraine. Read More

Year after buyout, Neximmune proceeds with $23M series A

Neximmune Inc. played its cards close to the vest after disclosing its acquisition a year ago by the Barer & Son Capital-led syndicate that included Sol Barer, chairman of Teva Pharmaceutical Industries Ltd. and former chairman and CEO of Celgene Corp., Joshua Barer, managing director of Sunflower Life Sciences, and William Hawkins, former chairman and CEO of Medtronic plc. Read More

New Year's IPOs seek warm reception

Just days before one of biotech's busiest weeks, a quartet of IPO filings by Menlo Therapeutics Inc., Restorbio Inc., Armo Biosciences Inc. and Solid Biosciences LLC are outlining the case for investing millions of dollars in the development of new therapies. Read More

ROI continues to decline for top pharma firms, according to Deloitte survey

LONDON – As the row over drug pricing gets louder, the return on investment (ROI) among the top 12 pharma companies continues to slide, according to the latest annual survey carried out by consultants at Deloitte LLP. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe